EGFR and head and neck squamous cell carcinoma: EGFR has been studied as a candidate for targeted drug therapy in HNSCC; however, while overexpression is seen in 80–90% of HNSCC, only 10–20% are responsive to anti-EGFR drug therapy [102,115,120,121].